Reversible Inhibition of Human Platelet Activation by Hypothermia In Vivo and In Vitro

Summary A hypothermia-induced hemorrhagic diathesis is associated with cardiopulmonary bypass, major surgery, and multiple trauma, but its pathophysiological basis is not well understood. We examined the hypothesis that hypothermia reversibly inhibits human platelet activation in vitro and in vivo. Platelet activation was studied in normal volunteers by whole blood flow cytometric analysis of modulation of platelet surface GMP-140 and the glycoprotein (GP) Ib-IX complex in: a) shed blood emerging from a standardized in vivo bleeding time wound; b) peripheral blood activated in vitro with either thrombin (in the presence of gly-pro-arg-pro, an inhibitor of fibrin polymerization) or the stable thromboxane (TX) A2 analogue U46619. Platelets in peripheral whole blood were activated at temperatures between 22° C and 37° C. the forearm skin temperature was maintained at temperatures between 22° C and 37° C prior to and during the bleeding time incision. Platelet aggregation was studied in shed blood by flow cytometry and in peripheral blood by aggregometry. Generation of TXB 2 (the stable metabolite of TXA 2) was determined by radioimmunoassay. In vitro, hypothermia inhibited both thrombin- and U46619-induced upregulation of GMP-140, downregulation of the GPIb-IX complex, platelet aggregation, and TXB2 generation. These inhibitory effects of hypothermia were all completely reversed by rewarming the blood to 37° C. In vivo, platelet activation was inhibited by hypothermia as shown by 5 independent assays of shed blood: upregulation of GMP-140, downregulation of the GPIb-IX complex, platelet aggregate formation, TXB 2 ggeneration, and the bleeding time. In summary, by a combination of immunologic, biochemical, and functional assays, we demonstrate that hypothermia inhibits human platelet activation in whole blood in vitro and in vivo. Rewarming hypothermic blood completely reverses the activation defect. These results suggest that maintaining normothermia or rewarming a hypothermic bleeding patient may reduce the need for platelet transfusions.

[1]  B. Pasche,et al.  The platelet function defect of cardiopulmonary bypass. , 1993, Blood.

[2]  G. Hempelmann,et al.  Platelet function in cardiac surgery: influence of temperature and aprotinin. , 1993, The Annals of thoracic surgery.

[3]  S. Khuri,et al.  Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. , 1992, The Journal of thoracic and cardiovascular surgery.

[4]  A. Michelson,et al.  High-dose heparin suppresses platelet alpha granule secretion. , 1992, Journal of vascular surgery.

[5]  R. Weisel,et al.  The effect of warm heart surgery on postoperative bleeding. , 1992, The Journal of thoracic and cardiovascular surgery.

[6]  A. Michelson Thrombin-Induced Down-Regulation of the Platelet Membrane Glycoprotein Ib-IX Complex , 1992, Seminars in thrombosis and hemostasis.

[7]  A. Michelson,et al.  Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. , 1991, Blood.

[8]  J. Macarthur,et al.  Hypothermia and acidosis worsen coagulopathy in the patient requiring massive transfusion , 1990 .

[9]  L. Harker,et al.  Bleeding complications associated with cardiopulmonary bypass. , 1990, Blood.

[10]  R. Rodgers,et al.  Bleeding Time Tables , 1990, Seminars in thrombosis and hemostasis.

[11]  J. Levin,et al.  A Critical Reappraisal of the Bleeding Time* , 1990, Seminars in thrombosis and hemostasis.

[12]  Janice,et al.  Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. , 1989, The Journal of clinical investigation.

[13]  C. Lambrew,et al.  Correlated measurement of platelet release and aggregation in whole blood. , 1989, Cytometry.

[14]  D. Mason,et al.  The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens , 1988, Histopathology.

[15]  E. Moore,et al.  Hypothermia-induced coagulopathies in trauma. , 1988, The Surgical clinics of North America.

[16]  A. Michelson,et al.  Platelet storage results in a redistribution of glycoprotein Ib molecules. Evidence for a large intraplatelet pool of glycoprotein Ib. , 1988, The Journal of clinical investigation.

[17]  M. Berndt,et al.  Ristocetin-dependent reconstitution of binding of von Willebrand factor to purified human platelet membrane glycoprotein Ib-IX complex. , 1988, Biochemistry.

[18]  A. Michelson,et al.  Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex. , 1987, Blood.

[19]  Xiaoping Du,et al.  Glycoprotein Ib and glycoprotein IX are fully complexed in the intact platelet membrane. , 1987, Blood.

[20]  F. Bel,et al.  Perinatal Factors and Periventricular-Intraventricular Hemorrhage in Preterm Infants , 1987 .

[21]  S. Khuri,et al.  Hypothermia-induced reversible platelet dysfunction. , 1987, Annals of surgery.

[22]  F. Bel,et al.  Perinatal Factors and Periventricular‐Intraventricular Hemorrhage in Preterm Infants , 1986, American journal of diseases of children.

[23]  H. Zola,et al.  Purification and preliminary characterization of the glycoprotein Ib complex in the human platelet membrane. , 1985, European journal of biochemistry.

[24]  M. Shuman,et al.  A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation , 1985, The Journal of cell biology.

[25]  R. McEver,et al.  A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. , 1984, The Journal of biological chemistry.

[26]  B. Furie,et al.  A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets. , 1984, The Journal of biological chemistry.

[27]  E. Hessel,et al.  Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. , 1980, Blood.

[28]  A. Babson,et al.  Development and evaluation of a disposable device for performing simultaneous duplicate bleeding time determinations. , 1978, American journal of clinical pathology.

[29]  E. Rossi Principles of transfusion medicine , 1996 .

[30]  J. George,et al.  Acquired abnormalities of platelet function [2] , 1991 .

[31]  G. Schiller,et al.  Acquired abnormalities of platelet function. , 1991, The New England journal of medicine.

[32]  A. Michelson Pathomechanism of Defective Hemostasis During and After Extracorporeal Circulation: The Role of Platelets , 1991 .

[33]  C. Abrams,et al.  Direct detection of activated platelets and platelet-derived microparticles in humans. , 1990, Blood.

[34]  McEver Rp Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. , 1990 .

[35]  R. McEver Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. , 1990, Blood cells.

[36]  R. Nachman,et al.  Molecular mechanisms of platelet aggregation. , 1986, Annual review of medicine.

[37]  S. P. Levine 10 – Secreted Platelet Proteins as Markers for Pathological Disorders* , 1986 .

[38]  B. Coller,et al.  Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. , 1983, Blood.

[39]  Judith C. Andersen Hemostasis and Thrombosis—Basic Principles and Clinical Practice , 1983 .